Diabetic Foot Ulcers (DFUs) and burn injuries pose significant challenges to healthcare professionals due to their complex nature and the potential for complications. Currently, there is a lack of objective and immediate diagnostic imaging products that utilize AI technology to assess the healing potential of these wounds.
DFUs affect millions of patients worldwide, and the comorbidities associated with diabetes further complicate the healing process. Existing diagnostic tools, such as trans-cutaneous oxygen measurement (TCOM), ankle-brachial index (ABI), and Doppler ultrasounds, provide limited information and do not accurately predict wound healing potential.
Burn experts, on average, achieve only 70% accuracy in assessing tissue viability, while non-specialists perform even worse, with accuracy below 50%. By utilizing AI technology, clinicians can make more informed decisions about surgical interventions, leading to improved patient outcomes and reduced risks.
Spectral AI (NASDAQ: $MDAI) could be the game-changer in the field of wound healing diagnostics. The multispectral imaging technology employed by DeepView® is truly revolutionary. By capturing multiple wavelengths of light, it unlocks the ability to extract unique tissue properties and structures that are imperceptible to the human eye. This comprehensive view of the wound serves as the foundation for precise and objective wound healing prediction.
KNOW MORE: